Endocrine Abstracts

Introduction: Mediastinal paragangliomas are rare. These tumours can be associated with increased morbidity and mortality when invasive growth to the heart, great vessels, esophagus and trachea occurs. Surgical resection, if feasible, is the treatment of choice.Case report: A 50-year-old man presented with severe and refractory left gluteal pain radiating to the posterior thigh for two months. The patient had no relevant medical history and no other symp...

Introduction: the presence of areas with a solid / trabecular growth pattern in differentiated papillary thyroid carcinoma (PTC) represents a source of controversy regarding clinical and prognostic significance and usually requires a more aggressive therapeutic approach. The aim of this study was to compare clinicopathological characteristics, treatments and prognosis of PTC with and without solid component (SC). We also aimed to evaluate whether SC affects patient outcome in ...

Background: Ectopic ACTH secretion from metastatic acinic cell carcinoma (ACC) of the parotid gland is extremely rare. ACC is an uncommon, typically indolent, salivary gland neoplasm. Herein, we report a case of a high-grade ACC later diagnosed with Cushing’s syndrome (CS).Case presentation: A 60-year-old man presented with a laterocervical mass. Computed tomography (CT) documented a 39×38 mm mass on the parotid gland and homolateral cervical l...

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...

Primary Aldosteronism (PA) is the most prevalent cause of secondary hypertension. The aim of this work was to characterize the diagnostic workup, treatment and follow-up of confirmed PA.The adrenal tumour study group of the Portuguese Society of Endocrinology undertook the first retrospective multicentre study of Portuguese PA patients. Data was gathered from nine Portuguese Endocrinology centres (three in the north, one in the centre and five in the sou...

Introduction: Adrenocortical carcinoma (ACC) is a rare entity, usually associated with a poor prognosis. There are still many areas of uncertainty regarding its approach.Methods: A Portuguese ACC register was established in 2020, including information from 24 endocrine centres. Kaplan-Meier was used to calculate overall survival and recurrence; log- rank test to assess survival and progression free survival (PFS) differences between groups; cox-regressio...